|
Thyroid Nodule
|
|
0.010 |
GeneticVariation
|
BEFREE |
Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes.
|
16756473 |
2006 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
Stomach Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Activated c-Ha-ras oncogene with a guanine to thymine transversion at the twelfth codon in a human stomach cancer cell line.
|
3034404 |
1987 |
|
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases.
|
7773929 |
1995 |
|
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
BRAF and KRAS mutations in stomach cancer.
|
14534542 |
2003 |
|
Squamous cell carcinoma of lung
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Squamous cell carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the KRAS gene showed only a G12C variation in one large cell carcinoma (LCC) patient, whereas variants were not found in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) cases.
|
30048458 |
2018 |
|
Split hand foot deformity 1
|
|
0.010 |
GeneticVariation
|
BEFREE |
There was 100% concordance between tissue and urinary cfDNA genotype in treatment-naïve samples. cfDNA analysis facilitated identification of previously undescribed KRAS(G12S)-mutant ECD and dynamically tracked disease burden in patients treated with a variety of therapies.
|
25324352 |
2015 |
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
|
Secondary malignant neoplasm of bone
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with KRAS G12C developed significantly more bone metastases compared with the remainder of the cohort (59% vs 16%, P<0.0001).
|
27336603 |
2016 |
|
Sebaceous adenoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A KRAS mutation G12C (c.34G>T, p.Gly12Cys) was detected in 1 sebaceous adenoma and a NRAS mutation Q61K (c.181C>A, p.Gln61Lys) was found in 2 other sebaceous adenomas.
|
27870730 |
2016 |
|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
Our study demonstrated that TRAIL significantly suppressed cell survival, by inducing apoptosis in a dose-dependent manner, in the pancreatic cancer BxPC-3 (wild type G12) and lung cancer A549 (G12S) cell lines.
|
20848283 |
2011 |